Search Results - "Beeram, M"

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas by Patnaik, A., Appleman, L.J., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Weiss, G.J., Sachdev, J.C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J.M., Lotze, M.T., Toledo, F.G.S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I., Ramanathan, R.K.

“…To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients…”
Get full text

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling by Beeram, M, Tan, Q-TN, Tekmal, RR, Russell, D, Middleton, A, deGraffenried, LA

“…Background: Resistance to endocrine therapy is a major impediment in breast cancer therapeutics. The Phosphatidylinositol-3-OH kinase (PI3K)/Protein kinase B…”
Get full text

329 A first-in-human study evaluating the safety and pharmacology of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors by Beeram, M, Lieu, C, Harb, W, Power, L, Kearns, J, Nering, R, Moyo, V, Wolf, B, Adjei, A

Get full text

Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients by Ng, Chee M., Patnaik, A., Beeram, M., Lin, C. C., Takimoto, C. H.

“…Purposes The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing…”
Get full text

96 Evaluation of hormone therapies in a panel of breast PDX models: Relevance of ER status on sensitivity to letrozole and tamoxifen by Wick, M.J, Vaught, T, Gamez, L, Meade, J, Diaz, A, Papadopoulos, K.P, Rasco, D.W, Patnaik, A, Beeram, M, Lang, A, Tolcher, A.W

Get full text

56 Establishment, Characterization and Evaluation of a Panel of Patient-derived Low Passage Breast Tumor Models by Wick, M, Vaught, T, Kelly, S, Farley, M, Tolcher, A, Rosenthal, A, Rodriguez, L, Beeram, M, Lang, A, Papadopoulos, K

Get full text

54P Establishment and characterization of luminal A breast PDX models from patients with acquired resistance to CDK 4/6 inhibitors by Wick, M.J., Flores, J., Moriarty, A., Beeram, M., Papadopoulos, K.

Get full text

395 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with erlotinib: clinical and preclinical experience by Patnaik, A, Besterman, J, Tolcher, A.W, Mehran, M, Drouin, M, Maroun, C, Bonfils, C, Beeram, M, Martell, R, Papadopoulos, K

Get full text

396 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with docetaxel: clinical and preclinical experience by O'Dwyer, P, Papadopoulos, K, Amaravadi, R, Harlacker, K, Beeram, M, Drouin, M, Mehran, M, Besterman, J, Maroun, C, Patnaik, A

Get full text

372 A phase I dose-escalation study of the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously to patients with advanced solid tumors by Weekes, C, Hedge, P, Xin, Y, Yu, R, Xiang, H, Gore, L, Beeram, M, Brachmann, R, Patnaik, A

Get full text

413 Phase II study evaluating the efficacy, safety and pharmacodynamic correlative study of dual anti-angiogenic inhibition using Bevacizumab (B) in combination with Sorafenib (S) in patients (pts) with advanced malignant melanoma by Mahalingam, D, Beeram, M, Rodon, J, Sankhala, K, Mita, A, Benjamin, D, Michalek, J, Tolcher, A, Wright, J, Sarantopoulos, J

Get full text

Lumbar puncture in the evaluation of possible asymptomatic congenital syphilis in neonates by Beeram, Madhava R., Chopde, Nitin, Dawood, Yousuf, Siriboe, Stella, Abedin, Mehnur

“…OBJECTIVE: To evaluate the usefulness of lumbar puncture (LP) in the initial evaluation of symptom-free infants for congenital syphilis. STUDY DESIGN: We…”
Get full text

Identification and molecular characterization of invasive lobular breast cancer models in a panel of 180 breast XPDX models by Flores, J., Moriarty, A., Lizette, F., Lang, A., Rosenthal, A., Papadopoulos, K., Beeram, M., Patnaik, A., Rasco, D., DeBerry, B., Elmi, M., Drengler, R., Hernandez, T., Sharma, M., Lakhani, N., Smith, L., Moreno, V., Calvo, E., Garcia-Foncillas, J., Wick, M.

Get full text

383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study by Jhaveri, K., Jeselsohn, R., Ma, C.X., Lim, E., Yonemori, K., Hamilton, E.P., Harnden, K., Im, S-A., Beck, T., Sammons, S., Bhave, M., Kaufman, P.A., Manich, C. Saura, Meniawy, T., Bacchion, F., Ismail-Khan, R., Li, Y., Estrem, S.T., Nguyen, B., Beeram, M.

Get full text

Raf: A Strategic Target for Therapeutic Development Against Cancer by BEERAM, Muralidhar, PATNALK, Amita, ROWINSKY, Eric K

“…The mitogen-activated protein kinase (MAPK) signaling pathway plays a critical role in transmitting proliferative signals generated by cell surface receptors…”
Get full text

209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors by Klempner, S.J., Beeram, M., Sabanathan, D., Chan, A., Hamilton, E., Loi, S., Oh, D-Y., Emens, L.A., Patnaik, A., Kim, J.E., Park, Y.H., Odegard, V., Hamke, S., Jang, G., Jacquemont, C., Hunder, N., Piha-Paul, S.A.

Get full text

2118 POSTER A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer by Krop, I.E, Beeram, M, Modi, S, Rabbee, N, Girish, S, Tibbitts, J, Holden, S.N, Lutzker, S.G, Burris, H.A

Get full text

7004 ORAL Phase II randomized, placebo controlled study of sorafenib in combination with dacarbazine in subjects with unresectable Stage III or Stage IV melanoma by McDermott, D, Sosman, J.A, Hodi, F.S, Gonzalez, R, Linette, G, Richards, J, Jakub, J.K, Beeram, M, Patel, K, Hersch, E

Get full text

A64 BRONCHOPULMONARY DYSPLASIA: Evaluating Maternal Preeclampsia As A Risk Factor For Developing Bronchopulmonary Dysplasia by Sagar, M, Ogborn, C, Beeram, M R, Raju, V N, Mallett, L

“…Mc Lane Children's Hospital/Baylor Scott and White, Temple, TX, Mc lane Children's Hospital/Baylor Scott and White, Temple, TX Corresponding author's email:…”
Get full text

Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers by McCaffery, I., Laport, G., Hotson, A., Willingham, S., Patnaik, A., Beeram, M., Miller, R.

Get full text